| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 4th January 2021 | Susan B Hirsch | 3,637 | Grant/award etc. | $3.78 | $13,747.86 |
| 31st December 2020 | Garo H Armen | 4,647 | Grant/award etc. | $3.18 | $14,777.46 |
| 18th December 2020 | Garo H Armen | 4,163 | Grant/award etc. | $3.55 | $14,778.65 |
| 4th December 2020 | Garo H Armen | 4,437 | Grant/award etc. | $3.33 | $14,775.21 |
| 25th November 2020 | Garo H Armen | 31,100 | Bona fide gift | $0.00 | |
| 24th November 2020 | Garo H Armen | 62,200 | Bona fide gift | $0.00 | |
| 20th November 2020 | Garo H Armen | 4,049 | Grant/award etc. | $3.65 | $14,778.85 |
| 6th November 2020 | Garo H Armen | 3,869 | Grant/award etc. | $3.82 | $14,779.58 |
| 23rd October 2020 | Garo H Armen | 3,751 | Grant/award etc. | $3.94 | $14,778.94 |
| 9th October 2020 | Garo H Armen | 3,397 | Grant/award etc. | $4.35 | $14,776.95 |
Agenus
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
Agenus, Inc. engages in the development and commercialization of technologies to treat cancers and infectious diseases. The company was founded by Garo H. Armen and Pramod K. Srivastava in March 1994 and is headquartered in Lexington, MA.
Ticker: AGEN
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1098972
Employees: 328
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
There were no Red Flags found
Fundamentals
Cash at Carrying Value: $79 M (28%)
Other Assets, Current: $1 M (27%)
Assets, Current: $105 M (21%)
Property, Plant and Equipment, Net: $29 M (8%)
Other Assets, Noncurrent: $1 M (2%)
Assets: $186 M (19%)
Long-term Debt, Current Maturities: $2 M (137%)
Accounts Payable, Current: $21 M (52%)
Accrued Liabilities, Current: $27 M (0%)
Liabilities, Current: $142 M (16%)
Long-term Debt, Excluding Current Maturities: $19 M (40%)
Other Liabilities, Noncurrent: $6 M (53%)
Common Stock, Value, Issued: $2 M (24%)
Common Stock, Shares, Issued: $171 M (24%)
Retained Earnings (Accumulated Deficit): $1 B (-1%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $369 Th (-72%)
Stockholders' Equity (Parent): $219 M (-2%)
Liabilities and Equity: $186 M (19%)
Revenue: $27 M (0%)
Research and Development: $39 M (-48%)
General and Administrative Expenses: $14 M (-42%)
Operating Income/Loss: $33 M (-45%)
Other Income, net: $340 Th (-75%)
News
XOMA: A Royalty Aggregator To Watch
4th January 2021
Completion of Balstilimab BLA Filing Extended To 1H2021
3rd December 2020
Agenus to Participate in Evercore ISI 3rd Annual HealthCONx Conference
25th November 2020
Agenus: A Buy With iNKT Therapy, MK-4830 Milestone
14th November 2020